RxDoctor Payments Data

Palak Krushiker, MD

Family Medicine · Bella Vista, ARNPI 1487273546

Payments from drug & device makers

$2,205in general payments, 2019–2025

Across 100 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$540
  • Amgen$407
  • Mylan Specialty L.p.$200
  • Inari Medical, Inc.$194
  • Astellas Pharma US Inc$146
  • Averitas Pharma Inc.$138
  • plus $580 from 15 others

What the payments were for

  • Food & beverage$2,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,205 in reported general payments places this provider in the 70th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$148,467
Medicare patients
338
Services billed
3,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$44,464
OzempicSemaglutide25$40,937
MounjaroTirzepatide30$37,710
XareltoRivaroxaban34$36,189
ProliaDenosumab19$33,040
JardianceEmpagliflozin27$28,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,004
FarxigaDapagliflozin Propanediol23$15,469
SymbicortBudesonide/Formoterol Fumarate17$5,123
Atorvastatin Calcium375$2,433
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,735
Albuterol Sulfate HfaAlbuterol Sulfate91$1,403
Losartan Potassium106$1,027
Metoprolol Succinate67$1,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$44,46440 claims
Novo NordiskOzempic$37$40,93725 claims
Lilly USA, LLCMounjaro$29$37,71030 claims
Johnson & JohnsonXarelto$35$36,18934 claims
AmgenProlia$407$33,04019 claims
Boehringer IngelheimJardiance$35$28,88927 claims
AstraZenecaFarxiga, Symbicort$13$20,59140 claims
AbbVieSynthroid$540$82818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Bella Vista

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →